Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
Dealbreaker on MSN11h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer DrugsClinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...
Evercore ISI analyst Cory Kasimov reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) on February 28 and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback